Why Kazia Therapeutics share price has skyrocketed today

The Kazia Therapeutics share price has soared after gaining US Food and Drug Administration approval to fast-track its drug trials

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Kazia Therapeutics Ltd (ASX: KZA) share price has skyrocketed 34% today after announcing the US Food and Drug Administration (FDA) had granted fast track designation (FTD) for Kazia's drug, paxalisib.

Paxalisib is used for the treatment of glioblastoma, which is the most common and aggressive form of primary brain cancer.

Key points

Fast track designation is a significant opportunity for Kazia Therapeutics because it speeds up the development of pharmaceutical products that demonstrate the potential to address unmet medical needs in serious or life-threatening conditions. 

Additionally, it provides Kazia with better access to the FDA, including opportunities for face-to-face meetings and written consultation throughout paxalisib's development. 

Companies with drugs given FTD designation are eligible to apply for accelerated approval and priority review. It could lead to faster product approval. 

Kazia Therapeutics CEO Dr James Garner said by awarding FTD to paxalisib, the FDA had recognised the drug's potential to meaningfully improve outcomes for patients with glioblastoma.

"This is a very powerful acknowledgement," Dr Garner said. "The opportunities that fast track designation creates, as we move towards an NDA filing, are of great value and have the potential to substantially accelerate the commercialisation of paxalisib…

"Additionally, the company is looking forward to working closely with the FDA as it moves into the final stage of development of the drug."

Where to next?

Kazia Therapeutics completed recruitment to its phase II clinical trial of paxalisib in newly diagnosed glioblastoma in February this year. It presented its interim clinical data at the American Association of Cancer Research (ACCR) virtual annual meeting II in June 2020. 

Pleasingly, the survival rate of Kazia's drug, paxalisib was calculated at 17.7 months which compares favourably to the existing FDA-approved standard of care drug, temozolomide, which is 12.7 months. 

The company expects to present further data from its study in the second half of this year and to finish the study early next year. 

Additionally, paxalisib has been selected to join the international GMB AGILE pivotal study in glioblastoma. Recruitment is expected to begin in the second half of this year. 

About Kazia Therapeutics share price

Kazia Therapeutics is an oncolgy-focused biotechnology company based in Sydney, Australia. Its pipeline includes two clinical-stage drug development candidates, and it's looking to develop therapies across a range of oncology indications.

The market has responded positively to today's news sending the share price up 33.94% at time of writing to be trading at $1.10. It has a market capitalisation of $104.5 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why Iluka, Sigma, Wildcat, and Woodside shares are falling today

These shares are having a tough time on hump day. Why are investors hitting the sell button?

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Bubs, Chrysos, JB Hi-Fi, and Paladin Energy shares are storming higher today

These shares are having a good time on hump day. But why?

Read more »

Man and woman sitting at casino table playing poker
Opinions

Australia's biggest winners in 2025? My money is on these 2 ASX shares

Here’s why I think these stocks could be underrated winners.

Read more »

Cheerful boyfriend showing mobile phone to girlfriend in dining room. They are spending leisure time together at home and planning their financial future.
Opinions

Here's how I'd invest my next $5,000 on the ASX in 2025

These two investments could make a lot of sense this year.

Read more »

A view of New York at sunrise looking from inside an aeroplane window.
Growth Shares

2 ASX growth shares I'd buy that could benefit from Trump

These stocks look to me like compelling options in the years ahead.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Wednesday

Another good session is expected for Aussie investors today.

Read more »

Happy diverse colleagues or team of people give high five together to celebrate great teamwork and results.
52-Week Highs

8 ASX 200 shares smashing 52-week highs today

These stocks hit new highs amid a turbulent day for the ASX 200.

Read more »